Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Talphera (NASDAQ:TLPH) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $6.00 target price on the stock.

Separately, Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Down 5.9 %

NASDAQ:TLPH opened at $0.63 on Tuesday. Talphera has a twelve month low of $0.50 and a twelve month high of $1.61. The stock has a market cap of $10.73 million, a P/E ratio of -0.91 and a beta of 0.28. The firm’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.82.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC bought a new position in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned approximately 11.73% of Talphera as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.